Judit Nyirady - Concepedia

Author

Judit Nyirady

Novartis (United States)

Also Known As

J Nyirady, J. Nyirady, Judit Nyirady, Nyirady, Judit

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)University of Alabama at Birmingham Icahn School of Medicine at Mount Sinai Johnson & Johnson (United States)

About

Judit Nyirady is an author at Novartis (United States) specializing in dermatology, medicine, and ophthalmology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	313
2	Social Sciences	1	1	28
3	Biomedical Engineering	1	1	14
4	Biomolecular Engineering	1	1	42
5	Diagnostic Sciences	1	1	71

Judit Nyirady

Publications

Citations

H-Index

Page 1

	Year	Citations
Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials∗ Boni E. Elewski, Héctor Cáceres, Liberation DeLeon, Journal of the American Academy of Dermatology Oral Griseofulvin SuspensionPediatricsOral MedicineDermatologyTinea Capitis	2008	125
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study Jerry Bagel, Kristina Callis Duffin, Angela Moore, Journal of the American Academy of Dermatology	2017	109
Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild‐to‐moderate toenail onychomycosis: results from three randomized studies using double‐blind vehicle‐controlled and open‐label active‐controlled designs Boni E. Elewski, Mahmoud A. Ghannoum, P. Mayser, Journal of the European Academy of Dermatology and Venereology Mild‐to‐moderate Toenail OnychomycosisRandomized StudiesNail ThicknessPrimary EndpointClinical Dermatology	2011	71
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis Gerard Bruin, Christian Loesche, Judit Nyirady, The Journal of Clinical Pharmacology InflammationAutoimmune DiseaseMedicineHuman Monoclonal AntibodySevere Psoriasis	2017	67
Long-Term Efficacy and Safety of Tretinoin Emollient Cream 0.05% in the Treatment of Photodamaged Facial Skin Sewon Kang, Wilma F. Bergfeld, Alice B. Gottlieb, American Journal of Clinical Dermatology Long-term EfficacyOphthalmologyClinical DermatologySkin PharmacologyDermatology	2005	62
Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled <scp>JUNCTURE</scp> trial J.‐P. Lacour, C. Paul, S. Jazayeri, Journal of the European Academy of Dermatology and Venereology	2017	57
The Psoriasis Symptom Diary: development and content validity of a novel patient‐reported outcome instrument Mark Lebwohl, Andrine R. Swensen, Judit Nyirady, International Journal of Dermatology	2013	55
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy James A. Simon, François Laliberté, Mei Sheng Duh, Menopause The Journal of The North American Menopause Society	2016	55
Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomized, double‐blind comparison Bárður Sigurgeirsson, Boni E. Elewski, Phoebe Rich, Journal of Dermatological Treatment	2006	43
The stability of tretinoin in tretinoin gel microsphere 0.1%. Judit Nyirady, Carmelle Lucas, Mohammad Yusuf, PubMed Biopolymer GelPhotochemistryTopical TretinoinMedicineTretinoin Gel	2002	42

Page 1